Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT05385991
Registration number
NCT05385991
Ethics application status
Date submitted
17/05/2022
Date registered
23/05/2022
Date last updated
24/10/2023
Titles & IDs
Public title
Booster Dose Study to Assess the Safety and Immunogenicity of ACM-001 Administered Intramuscularly or Intranasally.
Query!
Scientific title
An Open Label, Randomized, Dose and Route of Administration Comparison Phase 1 Study to Evaluate the Safety and Immunogenicity of the ACM-SARS-CoV-2-beta With ACM-CpG Vaccine Candidate (ACM-001), Administered Intramuscularly or Intranasally as a Booster Dose in Healthy Adults Aged 18 to 55 Years, Who Were Previously Vaccinated Against SARS-CoV-2.
Query!
Secondary ID [1]
0
0
ACM-001-01
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
SARS-CoV-2 Infection
0
0
Query!
Condition category
Condition code
Infection
0
0
0
0
Query!
Other infectious diseases
Query!
Respiratory
0
0
0
0
Query!
Other respiratory disorders / diseases
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Other interventions - ACM-SARS-CoV-2-beta ACM-CpG vaccine candidate (ACM-001)
Experimental: SARS-CoV-2 beta S vaccine arm 1 - SARS-CoV-2 beta S vaccine Antigen dose 1, no adjuvant, IM
Experimental: SARS-CoV-2 beta S vaccine arm 2 - SARS-CoV-2 beta S vaccine Antigen dose 1, no adjuvant, IN
Experimental: SARS-CoV-2 beta S vaccine arm 3 - SARS-CoV-2 beta S vaccine Antigen dose 2, adjuvant dose 1, IM
Experimental: SARS-CoV-2 beta S vaccine arm 4 - SARS-CoV-2 beta S vaccine Antigen dose 2, adjuvant dose 1, IN
Experimental: SARS-CoV-2 beta S vaccine arm 5 - SARS-CoV-2 beta S vaccine Antigen dose 1, adjuvant dose 1, IM
Experimental: SARS-CoV-2 beta S vaccine arm 6 - SARS-CoV-2 beta S vaccine Antigen dose 1, adjuvant dose 1, IN
Experimental: SARS-CoV-2 beta S vaccine arm 7 - SARS-CoV-2 beta S vaccine Antigen dose 1, adjuvant dose 2, IM
Experimental: SARS-CoV-2 beta S vaccine arm 8 - SARS-CoV-2 beta S vaccine Antigen dose 1, adjuvant dose 2, IN
Other interventions: ACM-SARS-CoV-2-beta ACM-CpG vaccine candidate (ACM-001)
ACM-SARS-CoV-2-beta ACM-CpG vaccine candidate (ACM-001): Artificial Cell Membranes (ACM) containing recombinant SARS-CoV-2, beta- variant strain, spike protein and ACMs containing CpG adjuvant
Query!
Intervention code [1]
0
0
Other interventions
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Adverses events
Query!
Assessment method [1]
0
0
Frequency, duration and intensity of solicited local AEs reported during 7 days following vaccination: injection site pain, erythema/redness (including size), and swelling/induration (including size) after IM injection, or nose pain, ear pain, runny nose, sneezing, stuffy nose and throat pain after IN administration.
Query!
Timepoint [1]
0
0
through study completion, an average of 6 months
Query!
Secondary outcome [1]
0
0
Immune responses
Query!
Assessment method [1]
0
0
Humoral and mucosal immune responses
Query!
Timepoint [1]
0
0
through study completion, an average of 6 months
Query!
Eligibility
Key inclusion criteria
1. Signed informed consent prior to any study-related procedure;
2. Subjects must have received a complete primary vaccination schedule and a third and/or
fourth booster dose with registered and commercial vaccine(s) against SARS-CoV-2, of
which the last dose was given at least 3 months prior to study vaccination (maximum of
1,000 IU of anti-S IgG);
3. Healthy males and females, 18-55 years of age, inclusive at screening;
4. Body mass index (BMI) = 18.0 and < 30.0 kg/m2;
5. Good health, based upon the results of medical history, physical examination, vital
signs, laboratory profiles of both blood and urine, and according to the clinical
judgement of the investigator;
6. Female participants of childbearing potential must be willing to comply with effective
contraception up to 90 days after the study vaccine administration;
7. Willing to comply with the study procedures.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
55
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
- 1. Known immune deficiency; 2. Chronic airway disease; 3. Has experienced an acute
illness, as determined by the investigator, or fever (>38.5°C) within 72 hours prior
to study vaccine administration; in such case, the subject may be screened again after
normalization of the temperature and/or healing of the illness; 4. Active hay fever or
other active allergies involving the lower airways (bronchial and pulmonary); 5.
Laboratory-confirmed PCR positive result for SARS-CoV-2 in nose/throat swab during
screening; 6. Previous participation in a study to evaluate a non-registered COVID-19
vaccine within 3 months prior to study vaccination; 7. Received any other commercial
vaccine within the 28 days prior to enrolment in the study, or immunization planned
within 3 months after enrolment in the study (influenza vaccines are allowed up to one
week before and one week after study vaccination; Exclusion criteria CONFIDENTIAL
Cohort 2: 15 µg Protein (N=10), IN Cohort 4: 5 µg Protein, 25 µg CpG (N=10), IN Cohort
6: 15 µg Protein, 25 µg CpG (N=10), IN Cohort 8: 15 µg Protein, 125 µg CpG (N=10), IN
ACM-001-01 Version 2.0 09 May 2022 Page 10 of 74 DocuSign Envelope ID:
C34D91C3-4686-427D-BB78-CF7178216E74 CONFIDENTIAL 8. Any confirmed severe allergic
reactions (urticaria, angioedema or anaphylaxis); 9. Evidence of any other active or
chronic disease (hematologic, renal, hepatic, cardiovascular, neurologic, endocrinal,
gastrointestinal, oncologic, pulmonary, immunologic or psychiatric disorders) or
condition that could interfere with, or for which the treatment of might interfere
with the conduct of the study, or that would pose an unacceptable risk to the subject
in the opinion of the investigator (following a detailed medical history, physical
examination, vital signs (systolic and diastolic blood pressure, and body
temperature). Minor deviations from the normal range may be accepted, if judged
without clinical relevance by the Investigator; 10.
Clinicallysignificantabnormalities,asjudgedbytheInvestigator,in laboratory test
results (including blood chemistry, hematology and urinalysis). In the case of
uncertain or questionable results, tests performed during screening may be repeated
before randomization to confirm eligibility or judged to be clinically irrelevant for
healthy subjects; 11. Positive hepatitis B surface antigen, hepatitis C antibody, or
human immunodeficiency virus antibody at screening; 12. Asplenia; 13.
Useofanychronictreatmentwithsystemiccorticosteroids(episodic treatments with topical
and intranasal corticosteroids are allowed) and immunosuppressive drugs; 14. Use of
paracetamol or non-steroidal anti-inflammatory drugs (NSAIDs) within 72 hours prior to
vaccination; 15. Receivedbloodproducts(transfusionsorimmunoglobulins)within3 months
prior to screening, or planned administration of blood products or immunoglobulins
during the study; 16. History of substance use disorder (alcohol, illegal substances),
current alcohol use disorder (according to Australian guidelines:
https://www.health.gov.au/news/australian-alcohol-guidelines- revised) or drug abuse;
17. Participation in an investigational drug or device study within 3 months prior to
first study vaccine administration or more than 4 times a year; 18.
Lossordonationofbloodover500mLwithin3months(males)or4 months (females) prior to
screening or intention to donate blood or blood products during the study; 19. History
of bleeding disorder (e.g., factor deficiency, coagulopathy, or platelet disorder
requiring special precautions), significant bleeding or bruising following IM
injections or venous punctures, or currently receiving anticoagulants; 20. Has body
art (e.g., tattoos), skin lesions or abnormalities that could interfere with the
observation of injection site reactions; ACM-001-01 Version 2.0 09 May 2022 Page 11 of
74
DocuSign Envelope ID: C34D91C3-4686-427D-BB78-CF7178216E74 Endpoints 21. Close contact with
laboratory-confirmed COVID-19 cases within 10 days prior to vaccination, high risk of
exposure or has an occupation with a high risk of exposure to SARS-CoV-2 (emergency
response); 22. Pregnancy confirmed by a positive pregnancy test, lactation or intention to
become pregnant during the study; 23. Any cancer diagnosed and/or treated within the past 5
years (except basal cell carcinoma of the skin and cervical carcinoma in situ); 24. Veins
not suitable for repeated blood sampling; 25. Serious reaction, such as anaphylactic
reaction, following primary COVID-19 vaccination; 26. Any known factor, condition, or
disease that might interfere with treatment compliance, study conduct or interpretation of
the results; 27. Sponsor employees or Investigator site personnel directly affiliated with
this study, and their immediate families. Immediate family is defined as a spouse, parent,
child or sibling, whether biological or legally adopted, including children of newly
composed families.
Query!
Study design
Purpose of the study
Prevention
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Other
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/07/2022
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
22/08/2023
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
38
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD
Query!
Recruitment hospital [1]
0
0
Paratus Research Central Coast - Kanwal
Query!
Recruitment hospital [2]
0
0
Paratus Research Sydney - Sydney
Query!
Recruitment hospital [3]
0
0
Paratus research Brisbane - Brisbane
Query!
Recruitment hospital [4]
0
0
Paratus research Canberra - Canberra
Query!
Recruitment hospital [5]
0
0
Emeritus Research Melbourne - Melbourne
Query!
Recruitment hospital [6]
0
0
Emeritus Research Sydney - Sydney
Query!
Recruitment postcode(s) [1]
0
0
2259 - Kanwal
Query!
Recruitment postcode(s) [2]
0
0
- Sydney
Query!
Recruitment postcode(s) [3]
0
0
4010 - Brisbane
Query!
Recruitment postcode(s) [4]
0
0
ACT 2617 - Canberra
Query!
Recruitment postcode(s) [5]
0
0
- Melbourne
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
ACM Biolabs
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
An open label, randomized, dose comparison, sequential cohorts study design in healthy
volunteers (young adults) is a frequently used design in vaccine Phase 1 studies.
ACM-001 is developed as a booster vaccine against SARS-CoV-2 after a full primary vaccination
with or without 1-2 booster doses (2 or 3 or 4 doses) schedule with any registered and
commercial SARS-CoV-2 vaccines.
The plan is to start with a low dosage of antigen alone, followed by a combination of antigen
and adjuvant and then to progress to higher dosages to define the safety profile of the
candidate vaccine as primary endpoint, and its immunogenicity as secondary endpoint.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT05385991
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT05385991
Download to PDF